ArticleNature2025
Targeting de novo purine biosynthesis for tuberculosis treatment.
Abstract read
In one paragraph
Article in Nature, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Itaconic Acid Directly Binds to the Cysteine Residue of PurF: A Novel Mechanism for Inhibiting Purine Metabolism in Porcine PathogenicMicroorganisms · 2026Article
- De novo or Salvage? Nucleotide Availability as a Driver of Bacterial Adaptation and Virulence.MicrobiologyOpen · 2026Review
- Nucleotide Metabolism in Health and Disease.MedComm · 2026Review
- Baloxavir Exhibits Antibacterial Activity AgainstInternational journal of molecular sciences · 2026Article
- Menaquinone depletion resensitises bedaquiline-resistant tuberculosis.bioRxiv : the preprint server for biology · 2026Article
- Targeting opportunities presented by the pyrimidine biosynthesis pathway in Mycobacterium tuberculosis: a brief review.Biochemical Society transactions · 2026Review
- Structure, Function, and Inhibition of Adenylosuccinate Lyase (ADSL) fromACS infectious diseases · 2026Article
- De novo nucleotide biosynthesis and its dynamic regulation are crucial for systemic infection by extraintestinal Escherichia coli.PLoS pathogens · 2026Article
- A non-enzymatic role of Nudix hydrolase 5 in repressing purine de novo synthesis.Science (New York, N.Y.) · 2025Article
- NUDT5 regulates purine metabolism and thiopurine sensitivity by interacting with PPAT.Science (New York, N.Y.) · 2025Article
- Review
- The role of cytochrome bcNature communications · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
46 authors.
Dirk A Lamprecht *Janssen Global Public Health, LLC, Janssen Pharmaceutica NV, Antwerp, Belgium. dirk.lamprecht@uct.ac.za.ORCID 0000-0003-1066-9026
Richard J Wall *Department of Infection Biology, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, UK.ORCID 0000-0003-3487-3187
Annelies Leemans *Janssen Global Public Health, LLC, Janssen Pharmaceutica NV, Antwerp, Belgium.
Barry TruebodyAfrica Health Research Institute, University of KwaZulu Natal, Durban, South Africa.
Joke SprangersJanssen Global Public Health, LLC, Janssen Pharmaceutica NV, Antwerp, Belgium.
Patricia FiogbeJanssen Global Public Health, LLC, Janssen Pharmaceutica NV, Antwerp, Belgium.
Cadi DaviesDepartment of Infection Biology, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, UK.
Jennefer WetzelJanssen Global Public Health, LLC, Janssen Pharmaceutica NV, Antwerp, Belgium.
Stijn DaemsJanssen Global Public Health, LLC, Janssen Pharmaceutica NV, Antwerp, Belgium.ORCID 0009-0005-6778-203X
William PearsonDepartment of Infection Biology, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, UK.ORCID 0000-0003-4146-9422
Vanessa PillayAfrica Health Research Institute, University of KwaZulu Natal, Durban, South Africa.
Samantha SaylockJanssen Research and Development, LLC, Janssen Pharmaceutica, Spring House, PA, USA.
M Daniel RickettsJanssen Research and Development, LLC, Janssen Pharmaceutica, Spring House, PA, USA.
Ellie DavisDepartment of Infection Biology, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, UK.
Adam HuffJanssen Research and Development, LLC, Janssen Pharmaceutica, Spring House, PA, USA.
Tsehai GrellJanssen Research and Development, LLC, Janssen Pharmaceutica, Spring House, PA, USA.
Shiming LinVaccine and Infectious Disease Organization, University of Saskatchewan, Saskatoon, Saskatchewan, Canada.
Michelle GerberVaccine and Infectious Disease Organization, University of Saskatchewan, Saskatoon, Saskatchewan, Canada.
Ann VosJanssen Research and Development, LLC, Janssen Pharmaceutica NV, Antwerp, Belgium.ORCID 0000-0001-9018-5878
John DallowDepartment of Infection Biology, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, UK.
Sam J WillcocksDepartment of Infection Biology, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, UK.
Christine RoubertEvotec ID (LYON) SAS, Lyon, France.
Stéphanie SansEvotec ID (LYON) SAS, Lyon, France.
Amandine DesormeEvotec ID (LYON) SAS, Lyon, France.
Nicolas ChappatEvotec ID (LYON) SAS, Lyon, France.
Aurélie RayEvotec ID (LYON) SAS, Lyon, France.
Mariana Pereira MoraesDepartment of Molecular Biology and Microbiology, Tufts University School of Medicine and Stuart B. Levy Center for Integrated Management of Antimicrobial Resistance, Boston, MA, USA.ORCID 0009-0004-0962-2620
Tracy WashingtonDepartment of Molecular Biology and Microbiology, Tufts University School of Medicine and Stuart B. Levy Center for Integrated Management of Antimicrobial Resistance, Boston, MA, USA.
Hope D'ErasmoDepartment of Molecular Biology and Microbiology, Tufts University School of Medicine and Stuart B. Levy Center for Integrated Management of Antimicrobial Resistance, Boston, MA, USA.ORCID 0009-0003-5714-7724
Pavankumar SanchetiJanssen Research and Development, LLC, Janssen Pharmaceutica NV, Antwerp, Belgium.
Melissa EveraertsJanssen Research and Development, LLC, Janssen Pharmaceutica NV, Antwerp, Belgium.
Mario MonshouwerJanssen Global Public Health, LLC, Janssen Pharmaceutica NV, Antwerp, Belgium.
Jorge EsquiviasJanssen Research and Development, LLC, Janssen Pharmaceutica, Toledo, Spain.ORCID 0000-0001-6050-5092
Gerald Larrouy-MaumusCentre for Bacterial Resistance Biology, Department of Life Sciences, Faculty of Natural Sciences, Imperial College London, London, UK.ORCID 0000-0001-6614-8698
Ruxandra Draghia AkliJanssen Research and Development, LLC, Janssen Pharmaceutica, Spring House, PA, USA.ORCID 0000-0001-6372-4039
Helen FletcherDepartment of Infection Biology, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, UK.
Alexander S PymJanssen Global Public Health, LLC, Janssen Pharmaceutica, High Wycombe, UK.
Bree B AldridgeDepartment of Molecular Biology and Microbiology, Tufts University School of Medicine and Stuart B. Levy Center for Integrated Management of Antimicrobial Resistance, Boston, MA, USA.ORCID 0000-0003-2236-1424
Jansy P SarathyCenter for Discovery and Innovation, Hackensack Meridian Health, Nutley, NJ, USA.ORCID 0000-0002-1532-146X
Kathleen W ClancyJanssen Research and Development, LLC, Janssen Pharmaceutica, Spring House, PA, USA.
Bart StoopsJanssen Research and Development, LLC, Janssen Pharmaceutica NV, Antwerp, Belgium.
Neeraj DharVaccine and Infectious Disease Organization, University of Saskatchewan, Saskatoon, Saskatchewan, Canada.ORCID 0000-0002-5887-8137
Adrie J C SteynAfrica Health Research Institute, University of KwaZulu Natal, Durban, South Africa.ORCID 0000-0001-9177-8827
Paul JacksonJanssen Global Public Health, LLC, Janssen Pharmaceutica, La Jolla, CA, USA.
Clara Aguilar-PérezJanssen Global Public Health, LLC, Janssen Pharmaceutica NV, Antwerp, Belgium.ORCID 0000-0001-7438-9141
Anil KoulJanssen Global Public Health, LLC, Janssen Pharmaceutica NV, Antwerp, Belgium. anil.koul@lshtm.ac.uk.ORCID 0009-0009-5542-4568
Funding
A Global Research Resource for Human TuberculosisR24AI186591 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI ADRIE JC STEYN · 2024 to 2026
$3.5MMETABOLIC REPROGRAMMING OF T CELL ENERGY METABOLISM IN TUBERCULOSIS AND HIVR33AI138280 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI STEYN, ADRIE JC · 2020 to 2023
$2.0MGates Foundation INV-027276NIAID NIH HHS R24 AI186591NIAID NIH HHS R33 AI138280Wellcome Trust
Abstract
Tuberculosis remains the leading cause of death from an infectious disease
Indexed as
Antitubercular AgentsMycobacterium tuberculosisPurinesTuberculosisAnimalsDNA ReplicationFemaleHumansLungMaleMiceMice, Inbred C57BLProof of Concept StudyTuberculosis, Multidrug-ResistantAntitubercular AgentspurinePurines
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.